Q4 2024
Released Feb 4, 2025, before the open
10-K filed Feb 27, 2025, 58 days after period end · 0000078003-25-000054
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$17.76B$17.76B derived+199.5% vs Q4 2023+0.3% vs Q3 2024
Net Income$410.00M$410.00M derivedN/M vs Q4 2023−90.8% vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived$6,721,000,000+28.3%
Free Cash Flowderived$5,804,000,000+38.3%
Margins · derived
Net margin2.3%+59.1 pt vs Q4 2023
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $17.76B | $5.93B | $15.75B | $16.19B |
| Net Income | $410.00M | -$3.37B | $4.99B | $3.39B |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR